GLP-1 Receptor Agonists and SGLT2 Inhibitors in Type 2 Diabetes: Pleiotropic Cardiometabolic Effects and Add-on Value of a Combined Therapy
Drugs · 2024-11 · 84 (11) · 1347-1364
DOI: 10.1007/s40265-024-02090-9 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Drugs, online erschienen am 28.09.2024. Verfasst von André J Scheen. Beteiligte Einrichtung: Division of Diabetes, Nutrition and Metabolic Disorders, CHU Liège, Liège, Belgium. andre.scheen@chuliege.be. Hauptthemen laut MEDLINE: Diabetes Mellitus, Type 2, Sodium-Glucose Transporter 2 Inhibitors, Cardiovascular Diseases, Hypoglycemic Agents. Die Arbeit wurde bisher 49-mal zitiert (Crossref) und nennt 136 Literaturangaben.
Themen: Diabetes mellitus
Abstract (Originalsprache)
Glucagon-like peptide-1 receptor agonists (GLP-1RAs) and sodium-glucose cotransporter 2 inhibitors (SGLT2is) have proven efficacy and safety in randomized clinical trials and observational real-life studies. Besides improving glucose control, reducing body weight, and lowering arterial blood pressure (surrogate endpoints), the breakthroughs were the demonstration of a significant reduction in cardiovascular and renal events in patients with type 2 diabetes at high risk. GLP-1RAs reduce events linked to atherogenic cardiovascular disease (especially ischemic stroke) and also renal outcomes (FLOW trial with semaglutide), with a limited effect on heart failure. The most striking protective effects of SGLT2is were a marked reduction in hospitalization for heart failure and a remarkable reduced progression of chronic kidney disease. These benefits have been attributed to numerous pleiotropic effects beyond glucose-lowering action. Underlying mechanisms contributing to cardiovascular and renal protection are at least partially different between GLP-1RAs (mainly anti-atherogenic and vascular effects) and SGLT2is (mainly systemic and intrarenal hemodynamic changes). Thus, patients at high risk may benefit from complementary actions when being treated with a GLP-1RA/SGLT2i combination. Such combination has proven its efficacy on surrogate endpoints. Furthermore, post hoc subgroup analyses of cardiovascular outcome trials have suggested a greater cardiorenal protection in patients treated with a combination versus either monotherapy. The benefits of a combined therapy have been confirmed in a few retrospective cohort studies. A dedicated prospective trial comparing a combined therapy versus either monotherapy is ongoing (PRECIDENTD); however, several challenges still remain, especially the higher cost of a combined therapy and the worldwide underuse of either GLP-1RAs or SGLT2is in clinical practice, even in patients at high cardiorenal risk.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Division of Diabetes, Nutrition and Metabolic Disorders, CHU Liège, Liège, Belgium. andre.scheen@chuliege.be.
- Division of Clinical Pharmacology, Centre for Interdisciplinary Research on Medicines (CIRM), Liège University, Liège, Belgium. andre.scheen@chuliege.be.
Zitieren
APA
Scheen, A. J. (2024). GLP-1 Receptor Agonists and SGLT2 Inhibitors in Type 2 Diabetes: Pleiotropic Cardiometabolic Effects and Add-on Value of a Combined Therapy. Drugs, 84(11), 1347-1364. https://doi.org/10.1007/s40265-024-02090-9
Vancouver
Scheen AJ. GLP-1 Receptor Agonists and SGLT2 Inhibitors in Type 2 Diabetes: Pleiotropic Cardiometabolic Effects and Add-on Value of a Combined Therapy. Drugs. 2024;84(11):1347-1364. doi:10.1007/s40265-024-02090-9
BibTeX
@article{Scheen2024,
author = {Scheen, André J},
title = {GLP-1 Receptor Agonists and SGLT2 Inhibitors in Type 2 Diabetes: Pleiotropic Cardiometabolic Effects and Add-on Value of a Combined Therapy},
journal = {Drugs},
year = {2024},
volume = {84},
number = {11},
pages = {1347--1364},
doi = {10.1007/s40265-024-02090-9}
}
EUVIMED